Current treatment of advanced papillary renal cell carcinoma

Despite significant improvements in the treatment outcomes of clear cell renal cell carcinoma (RCC), advanced/metastatic papillary RCC continues to have limited treatment options and there is clearly an unmet need. However, it is hoped that an optimal first-line treatment for papillary RCC will be identified in the next few years through the use of molecular […] [...]

read more

UK cancer survival rates lag behind other European countries

A recent study, commissioned by the Association of the British Pharmaceutical Industry (ABPI), reports that British cancer patients have the worst survival rates in Europe for nine out of ten major cancers.  The study found the UK had ‘below average rates of five-year survival in diseases such as bowel, lung, breast, ovarian, prostate and kidney cancer, […] [...]

read more

Recommendations for the management of rare kidney cancers

Patients diagnosed with a rare kidney cancer are often treated the same way as clear-cell renal cell carcinoma (ccRCC) patients, despite little evidence from randomised trials. Identifying the subtype of kidney cancer by looking at the genetic make-up of tumour cells to group patients by rare kidney cancer subtype may improve outcomes. Availability of potential […] [...]

read more

National Cancer Patient Experience Survey show patients are increasingly positive about their NHS cancer care

The annual National Cancer Patient Experience Survey (NCPES) published today shows improvement in patient experiences of NHS cancer care over the past year. The National Cancer Patient Experience Survey 2016 asked 72,788 people with cancer for their views on their care within NHS England. When asked to rate their care on a scale of zero (very […] [...]

read more

Type of long-term response to targeted therapy affects outcomes for advanced kidney cancer

A retrospective study conducted by researchers in the Czech Republic has analysed the outcomes of 219 people with metastatic renal cell carcinoma (mRCC) who received first-line treatment with vascular endothelial growth factor (VEGF) inhibitors, for example sunitinib, sorafenib, pazopanib, or bevacizumab, for at least 2 years. The vast majority of patients (166 patients, 75.8%) received […] [...]

read more

NHS comes out on top in a review of international healthcare systems

Here is some good news about the UK NHS: In a report published by the Commonwealth Fund last week, the UK healthcare system was rated first out of the healthcare systems in the following 11 countries: the UK, the US, Switzerland, Sweden, France, Germany, the Netherlands, Canada, New Zealand, Norway and Australia. The UK was […] [...]

read more
Showing 1 to 6 of 209 results